225 related articles for article (PubMed ID: 16166944)
1. Update on vaccines for solid tumors.
Gajewski TF
Clin Adv Hematol Oncol; 2004 Mar; 2(3):158-9. PubMed ID: 16166944
[No Abstract] [Full Text] [Related]
2. New frontiers in cell-based immunotherapy of cancer.
D'Elios MM; Del Prete G; Amedei A
Expert Opin Ther Pat; 2009 May; 19(5):623-41. PubMed ID: 19441938
[TBL] [Abstract][Full Text] [Related]
3. Recent developments in therapeutic cancer vaccines.
Morse MA; Chui S; Hobeika A; Lyerly HK; Clay T
Nat Clin Pract Oncol; 2005 Feb; 2(2):108-13. PubMed ID: 16264883
[TBL] [Abstract][Full Text] [Related]
4. Vaccines: an innovative approach to treating cancer.
Pazdur MP; Jones JL
J Infus Nurs; 2007; 30(3):173-8. PubMed ID: 17505219
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic cancer vaccines.
Morris LF; Ribas A
Surg Oncol Clin N Am; 2007 Oct; 16(4):819-31, ix. PubMed ID: 18022546
[TBL] [Abstract][Full Text] [Related]
6. Cancer vaccines and tumor dormancy: a long-term struggle between host antitumor immunity and persistent cancer cells?
Quesnel B
Expert Rev Vaccines; 2006 Dec; 5(6):773-81. PubMed ID: 17184216
[TBL] [Abstract][Full Text] [Related]
7. Tumor immunology at the service of cancer immunotherapy.
Finn OJ
Curr Opin Immunol; 2004 Apr; 16(2):127-9. PubMed ID: 15023402
[No Abstract] [Full Text] [Related]
8. [Development of personalized peptide vaccines for advanced cancer patients].
Yamada A
Rinsho Ketsueki; 2005 Jun; 46(6):433-8. PubMed ID: 16447725
[No Abstract] [Full Text] [Related]
9. Immunoprevention of cancer: time to reconsider timing of vaccination against cancer.
Spisek R
Expert Rev Anticancer Ther; 2006 Dec; 6(12):1689-91. PubMed ID: 17181481
[No Abstract] [Full Text] [Related]
10. Cancer vaccines: what do we need to measure in clinical trials?
Kudrin A
Hum Vaccin Immunother; 2014; 10(11):3236-40. PubMed ID: 25483508
[TBL] [Abstract][Full Text] [Related]
11. Tissue vaccines for cancer.
Suckow MA; Heinrich J; Rosen ED
Expert Rev Vaccines; 2007 Dec; 6(6):925-37. PubMed ID: 18377356
[TBL] [Abstract][Full Text] [Related]
12. Tumor antigens as surrogate markers and targets for therapy and vaccines.
Dalgleish A; Pandha H
Adv Cancer Res; 2007; 96():175-90. PubMed ID: 17161680
[TBL] [Abstract][Full Text] [Related]
13. Promises and limitations of murine models in the development of anticancer T-cell vaccines.
Lévy F; Colombetti S
Int Rev Immunol; 2006; 25(5-6):269-95. PubMed ID: 17169777
[TBL] [Abstract][Full Text] [Related]
14. Targeting targeted therapies.
Shingler W; Harrop R
Immunotherapy; 2010 Nov; 2(6):745-8. PubMed ID: 21091104
[No Abstract] [Full Text] [Related]
15. Molecular targeting with cancer vaccines.
Disis ML
J Clin Oncol; 2005 Aug; 23(22):4840-1. PubMed ID: 15983394
[No Abstract] [Full Text] [Related]
16. Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy.
Sigalotti L; Coral S; Fratta E; Lamaj E; Danielli R; Di Giacomo AM; Altomonte M; Maio M
Semin Oncol; 2005 Oct; 32(5):473-8. PubMed ID: 16210088
[TBL] [Abstract][Full Text] [Related]
17. Clinical development of MVA-based therapeutic cancer vaccines.
Acres B; Bonnefoy JY
Expert Rev Vaccines; 2008 Sep; 7(7):889-93. PubMed ID: 18767940
[TBL] [Abstract][Full Text] [Related]
18. Cancer vaccines: challenges and outlook in the field.
Paul S; Acres B; Limacher JM; Bonnefoy JY
IDrugs; 2007 May; 10(5):324-8. PubMed ID: 17487784
[TBL] [Abstract][Full Text] [Related]
19. Xenogenic cancer vaccines.
Potebnya GP; Symchych TV; Lisovenko GS
Exp Oncol; 2010 Jul; 32(2):61-5. PubMed ID: 20693963
[TBL] [Abstract][Full Text] [Related]
20. Challenges for cancer vaccine development.
Tabi Z; Man S
Adv Drug Deliv Rev; 2006 Oct; 58(8):902-15. PubMed ID: 16979786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
